ENTRY       D11463                      Drug
NAME        Mosunetuzumab (USAN/INN);
            Mosunetuzumab (genetical recombination) (JAN);
            Mosunetuzumab-axgb;
            Lunsumio (TN)
PRODUCT     LUNSUMIO (Genentech)
FORMULA     C6515H10031N1725O2025S43
EXACT_MASS  146209.2967
MOL_WEIGHT  146299.4941
SEQUENCE    (A chain)
            EVQLVQSGAE VKKPGASVKV SCKASGYTFT NYYIHWVRQA PGQGLEWIGW IYPGDGNTKY
            NEKFKGRATL TADTSTSTAY LELSSLRSED TAVYYCARDS YSNYYFDYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
            TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLVS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (B chain)
            DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSRTRKNYLA WYQQKPGQPP KLLIYWASTR
            ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCTQSFIL RTFGQGTKVE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (C chain)
            EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYNMHWVRQA PGKGLEWVGA IYPGNGDTSY
            NQKFKGRFTI SVDKSKNTLY LQMNSLRAED TAVYYCARVV YYSNSYWYFD VWGQGTLVTV
            SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
            YGSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
            EEMTKNQVSL WCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
            RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
            (E chain)
            DIQMTQSPSS LSASVGDRVT ITCRASSSVS YMHWYQQKPG KAPKPLIYAP SNLASGVPSR
            FSGSGSGTDF TLTISSLQPE DFATYYCQQW SFNPPTFGQG TKVEIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: A22-A96, A146-A202, A222-B219, A228-C231, A231-C234, A263-A323, A369-A427, B23-B94, B139-B199, C22-C96, C149-C205, C225-D213, C266-C326, C372-C430, D23-D87, D133-D193)
  TYPE      Peptide
REMARK      Product: D11463<US>
EFFICACY    Antineoplastic
  DISEASE   Follicular lymphoma [DS:H01613]
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of hematologic malignancies
TARGET      CD3E [HSA:916] [KO:K06451]
            CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(916+931)  Hematopoietic cell lineage
BRITE       USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Mosunetuzumab
                D11463  Mosunetuzumab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D11463  Mosunetuzumab (USAN/INN) &lt;US&gt;
                CD20
                 D11463  Mosunetuzumab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11463
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11463
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11463
DBLINKS     CAS: 1905409-39-3
            PubChem: 384585439
///
